Advance Search
XU Haixia, ZHU Chunlan, ZHANG Zunsheng, XIA Yidong, ZHANG Yu. Impact of Yougui Pill combined with modified Erchen Decoction in treating polycystic ovary syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(10): 107-111, 115. DOI: 10.7619/jcmp.20210056
Citation: XU Haixia, ZHU Chunlan, ZHANG Zunsheng, XIA Yidong, ZHANG Yu. Impact of Yougui Pill combined with modified Erchen Decoction in treating polycystic ovary syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(10): 107-111, 115. DOI: 10.7619/jcmp.20210056
shu

Impact of Yougui Pill combined with modified Erchen Decoction in treating polycystic ovary syndrome

  • 1.

    Department of Gynecology, The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137

  • 2.

    Department of Gynecology, Shanghai Hospital of Traditional Chinese Medicine, Shanghai, 200071

More Information
  • Received Date: January 03, 2021
  • Available Online: June 01, 2021
  • Published Date: May 27, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To observe the efficacy of Yougui Pill combined with modified Erchen Decoction in treating patients with polycystic ovary syndrome (PCOS), and its impact on serum angiopoietin-like protein (Angptl)-2, Angptl-4 and soluble fms-like tyrosine kinase receptor (sFlt)-1.
      Methods  A total of 92 PCOS patients were divided into observation group and control group according to the random numerical method, with 46 cases in each group. The control group was treated with conventional western medicine, and the observation group was treated with Yougui Pill combined with modified Erchen Decoction on the basis of the control group. The efficacy and incidence of adverse reactions were compared between the two groups and the acne score, cervical mucus score, ovarian volume, follicle number, estradiol, luteinizing hormone, follicle stimulating hormone, prolactin, resistance index (RI), pulsatility index (PI), mean blood flow velocity (Vm), Angptl-2, Angptl-4 and sFlt-1 levels were compared in two groups before and after treatment.
      Results  The total effective rate in observation group was 95.65%, which was significantly higher than 78.26% in control group (P < 0.05). The incidence of adverse reactions in the observation group was 4.35%, which was significantly lower than 19.57% in the control group (P < 0.05). After treatment, the acne score, RI, PI, Vm, estradiol, luteinizing hormone, follicle stimulating hormone, prolactin, Angptl-2 and sFlt-1 levels of two groups were lower than treatment before, and were lower in the observation group than those in the control group(P < 0.01). After treatment, the ovarian volume in the two groups was smaller, and the number of follicles was less than that before treatment(P < 0.01). The ovarian volume was smaller and the number of follicles in the observation group was less than those in the control(P < 0.01). After treatment, the cervical mucus score and the level of Angptl-4 in the two groups were higher than before treatment, and the observation group was significantly higher than the control group (P < 0.01).
      Conclusion  Yougui Pill combined with modified Erchen Decoction in the treatment of polycystic ovary syndrome is obvious, which can significantly improve symptoms, reduce hormone levels and improve uterine blood circulation. The action mechanism may be related to the reduction of serum Angptl-2, Angptl-4 and sFlt-1 levels.
    • FullText(HTML)
    • References (15)
  • [1]
    ESCOBAR-MORREALE H F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14(5): 270-284. doi: 10.1038/nrendo.2018.24
    [2]
    LIZNEVA D, SUTURINA L, WALKER W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome[J]. Fertil Steril, 2016, 106(1): 6-15. doi: 10.1016/j.fertnstert.2016.05.003
    [3]
    VATANNEJAD A, SALIMI F, MORADI N, et al. Evaluation of angiopoietin-like protein 3(ANGPTL3) levels in polycystic ovary syndrome[J]. Life Sci, 2020, 263: 118595. doi: 10.1016/j.lfs.2020.118595
    [4]
    LIU Z, LIU C, HAO C, et al. Aberrant expression of angiopoietin-like proteins 1 and 2 in cumulus cells is potentially associated with impaired oocyte developmental competence in polycystic ovary syndrome[J]. Gynecol Endocrinol, 2016, 32(7): 557-561. doi: 10.3109/09513590.2016.1138463
    [5]
    崔琳琳, 陈子江. 多囊卵巢综合征诊断标准和诊疗指南介绍[J]. 国际生殖健康/计划生育杂志, 2011, 30(5): 405-408. doi: 10.3969/j.issn.1674-1889.2011.05.018
    [6]
    刘宏奇. 中医妇科学[M]. 第2版. 北京: 科学出版社, 2011: 181-185.
    [7]
    刘艳, 段育华. 达英-35联合补肾化痰调经汤治疗肾虚痰湿型多囊卵巢综合征致月经后期[J]. 实用妇科内分泌电子杂志, 2019, 6(21): 72-73. https://www.cnki.com.cn/Article/CJFDTOTAL-FKDZ201921052.htm
    [8]
    刘成丽, 王丽丽, 曲凤占, 等. 右归丸联合小檗碱对多囊卵巢综合征胰岛素抵抗的研究[J]. 现代生物医学进展, 2015, 15(20): 3943-3945. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201520040.htm
    [9]
    姚国晋, 孔立红, 杨柳, 等. 不同频率电针联合右归丸加减治疗肾虚型多囊卵巢综合征临床观察及对性激素、体质量指数的影响[J]. 河北中医, 2017, 39(7): 1005-1010. doi: 10.3969/j.issn.1002-2619.2017.07.011
    [10]
    Rahmani E, Akbarzadeh S, Broomand A, et al. Serum levels of angiopoietin-like protein 2 and obestatin in iranian women with polycystic ovary syndrome and normal body mass index[J]. J Clin Med, 2018, 7(7): 188-195. http://europepmc.org/abstract/MED/29932432
    [11]
    OSUMI H, HORIGUCHI H, KADOMATSU T, et al. Tumor cell-derived angiopoietin-like protein 2 establishes a preference for glycolytic metabolism in lung cancer cells[J]. Cancer Sci, 2020, 111(4): 1241-1253. doi: 10.1111/cas.14337
    [12]
    JUNG C H, LEE W J, LEE M J, et al. Association of serum angiopoietin-like protein 2 with carotid intima-media thickness in subjects with type 2 diabetes[J]. Cardiovasc Diabetol, 2015, 14(1): 1-8. doi: 10.1186/s12933-014-0162-3
    [13]
    GÜNEŞM, BUKAN N. Examination of angiopoietin-like protein 4, neuropeptide Y, omentin-1 levels of obese and non-obese patients with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2015, 31(11): 903-906. http://www.ncbi.nlm.nih.gov/pubmed/26291814
    [14]
    CINKAJZLOVA A, MRAZ M, LACINOVA Z, et al. Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation[J]. Nutr Diabetes, 2018, 8(1): 21. doi: 10.1038/s41387-018-0032-2
    [15]
    MCCULLOCH L J, BRAMWELL L R, KNIGHT B, et al. Circulating and tissue specific transcription of angiopoietin-like protein 4 in human Type 2 diabetes[J]. Metabolism, 2020, 106: 154192. doi: 10.1016/j.metabol.2020.154192
    • Related Articles

  • Cited by

    Periodical cited type(9)

    1. 胡武彩，周桂生. 尿八联检验联合定量尿培养在尿路感染中的诊断效能. 系统医学. 2024(03): 61-64 .
    2. 邱玉琳. 全血C反应蛋白和白细胞及尿常规联合检测对尿路感染的诊断价值. 医疗装备. 2024(15): 74-76 .
    3. 武颖，龚正，刘航，王美燕，燕慧. 2019—2020年北京市丰台中西医结合医院的尿细菌培养情况及药敏分析. 中国当代医药. 2023(11): 157-160 .
    4. 崔玉荣. 干化学法与尿沉渣法在尿常规检验中的应用价值. 实用检验医师杂志. 2023(03): 258-261 .
    5. 杨海东，周文博，罗景，段南均. 上尿路结石感染的病原学特征及即刻引流效果分析. 实用临床医药杂志. 2022(05): 71-74 . 本站查看
    6. 杨超，刘健，申忠华，崔海军，张慧民，郝俊秀，裴琼. 唐山市工人医院2018年-2021年泌尿系结石感染患者的细菌谱变迁及药敏特点分析. 中国现代医学杂志. 2022(15): 79-84 .
    7. 周旭瑜. Mejer-7001尿沉渣分析仪与细菌培养检查诊断尿路感染的一致性分析. 基层医学论坛. 2021(14): 2026-2027 .
    8. 宋培培，张琴，许健，王秦，刘成桂. 某三甲医院儿童和成年女性尿培养病原菌分布和耐药性分析. 现代生物医学进展. 2021(12): 2344-2349 .
    9. 郑萍萍，张丽华. 改良尿标本留取方式对中段尿培养结果的影响. 名医. 2021(22): 80-81 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (407) PDF downloads (15) Cited by(10)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return